You are here

  • Home
  • Online First
  • PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy

Article info

Article menu

other Versions

Download PDFPDF
Review
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy

Authors

  • Anca Chelariu-Raicu Department of Obstetrics and Gynecology, Breast Center, Gynecologic Cancer Center and CCC Munich, Ludwig Maximilians University Munich, Munich, Bayern, GermanyGerman Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center, Munich, Germany PubMed articlesGoogle scholar articles
  • Fabian Trillsch Department of Obstetrics and Gynecology, Breast Center, Gynecologic Cancer Center and CCC Munich, Ludwig Maximilians University Munich, Munich, Bayern, Germany PubMed articlesGoogle scholar articles
  • Alexander Burges Department of Obstetrics and Gynecology, Breast Center, Gynecologic Cancer Center and CCC Munich, Ludwig Maximilians University Munich, Munich, Bayern, Germany PubMed articlesGoogle scholar articles
  • Bastian Czogalla Department of Obstetrics and Gynecology, Breast Center, Gynecologic Cancer Center and CCC Munich, Ludwig Maximilians University Munich, Munich, Bayern, Germany PubMed articlesGoogle scholar articles
  • Anna Hester Department of Obstetrics and Gynecology, Breast Center, Gynecologic Cancer Center and CCC Munich, Ludwig Maximilians University Munich, Munich, Bayern, Germany PubMed articlesGoogle scholar articles
  • Rahel Wuerstlein Department of Obstetrics and Gynecology, Breast Center, Gynecologic Cancer Center and CCC Munich, Ludwig Maximilians University Munich, Munich, Bayern, Germany PubMed articlesGoogle scholar articles
  • Nadia Harbeck Department of Obstetrics and Gynecology, Breast Center, Gynecologic Cancer Center and CCC Munich, Ludwig Maximilians University Munich, Munich, Bayern, Germany PubMed articlesGoogle scholar articles
  • Sven Mahner Department of Obstetrics and Gynecology, Breast Center, Gynecologic Cancer Center and CCC Munich, Ludwig Maximilians University Munich, Munich, Bayern, GermanyGerman Cancer Consortium (DKTK), partner site Munich, German Cancer Research Center, Munich, Germany PubMed articlesGoogle scholar articles
  1. Correspondence to Dr Anca Chelariu-Raicu, Department of Obstetrics and Gynecology, Breast Center, Gynecologic Cancer Center and CCC Munich, Ludwig Maximilians University Munich, 81377 Munich, Bayern, Germany; Anca.Chelariu-Raicu{at}med.uni-muenchen.de
View Full Text

Citation

Chelariu-Raicu A, Trillsch F, Burges A, et al
PARP inhibitors: risk factors for toxicity and matching patients to the proper poly (ADP-ribose) polymerase inhibitor (PARPi) therapy
International Journal of Gynecologic Cancer Published Online First: 27 January 2023. doi: 10.1136/ijgc-2022-003990

Publication history

  • Received September 27, 2022
  • Accepted January 11, 2023
  • First published January 27, 2023.

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© IGCS and ESGO 2023. No commercial re-use. See rights and permissions. Published by BMJ.